AVA-101
AVA-101 is being developed to provide a safe and effective treatment for wet AMD that is durable and reduces the need for frequent injections. AVA-101 is comprised of the AAV2 vector, which contains a gene encoding sFLT-1, a naturally occurring anti-VEGF protein. When administered in the eye and expressed by the host retinal cells, the sFLT-1 protein inhibits the formation of new blood vessels and reduces vascular permeability by binding and blocking VEGF activity.
In Phase 1 and Phase 2a studies, AVA-101 was shown to be well-tolerated with no significant drug-related safety concerns.
